Correspondence 0001193125-24-084731 from Contineum Therapeutics, Inc. (CTNM)
Contineum Therapeutics, Inc.
Date: April 2, 2024 · CIK: 0001855175 · Accession: 0001193125-24-084731
AI Filing Summary & Sentiment
File numbers found in text: 333-278003
Letter
April 2, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4561
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention:
Daniel Crawford
Laura Crotty
Ibolya Ignat
Kevin Juhar
Re: Contineum Therapeutics, Inc.
Amendment No. 1 to Registration Statement on Form S-1
Filed April 1, 2024
File No. 333-278003
CIK No: 0001855175
Request for Acceleration of Effective Date
Requested Date: Thursday, April 4, 2024
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Contineum Therapeutics, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-278003) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, by calling Ryan Gunderson at (858) 436-8046.
[Signature page follows]
Securities and Exchange Commission
April 2, 2024
Page 2
Sincerely,
Contineum Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP April 2, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Daniel Crawford Laura Crotty Ibolya Ignat Kevin Juhar Re: Contineum Therapeutics, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed April 1, 2024 File No. 333-278003 CIK No: 0001855175 Request for Acceleration of Effective Date Requested Date: Thursday, April 4, 2024 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Contineum Therapeutics, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-278003) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, by calling Ryan Gunderson at (858) 436-8046. [Signature page follows] Securities and Exchange Commission April 2, 2024 Page 2 Sincerely, Contineum Therapeutics, Inc. By: /s/ Peter Slover Peter Slover Chief Financial Officer Contineum Therapeutics, Inc. cc: Carmine Stengone, Chief Executive Officer and President, Contineum Therapeutics, Inc. Jeffrey Thacker, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP Ryan J. Gunderson, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP Leanne A. Gould, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP Frank F. Rahmani, Sidley Austin LLP Samir A. Gandhi, Sidley Austin LLP J. Carlton Fleming, Sidley Austin LLP Kostian Ciko, Sidley Austin LLP